Short Interest in Synlogic, Inc. (NASDAQ:SYBX) Declines By 25.7%

Synlogic, Inc. (NASDAQ:SYBX) saw a significant decline in short interest during the month of January. As of January 15th, there was short interest totaling 7,729 shares, a decline of 25.7% from the December 31st total of 10,406 shares. Based on an average daily trading volume, of 14,860 shares, the short-interest ratio is presently 0.5 days. Approximately 0.1% of the company’s stock are short sold. Approximately 0.1% of the company’s stock are short sold. Based on an average daily trading volume, of 14,860 shares, the short-interest ratio is presently 0.5 days.

Institutional Investors Weigh In On Synlogic

An institutional investor recently bought a new position in Synlogic stock. Citadel Advisors LLC purchased a new position in Synlogic, Inc. (NASDAQ:SYBX) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 29,011 shares of the biotechnology company’s stock, valued at approximately $49,000. Citadel Advisors LLC owned approximately 0.25% of Synlogic at the end of the most recent reporting period. Institutional investors own 63.40% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Synlogic in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Synlogic Stock Performance

Synlogic stock remained flat at $0.63 during midday trading on Friday. The company had a trading volume of 7,077 shares, compared to its average volume of 244,894. The company has a market cap of $7.37 million, a PE ratio of -2.42 and a beta of 0.39. Synlogic has a 52 week low of $0.54 and a 52 week high of $1.96. The business’s 50 day moving average price is $1.10 and its two-hundred day moving average price is $1.42.

Synlogic (NASDAQ:SYBX) last issued its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.08). As a group, research analysts predict that Synlogic will post -2.71 EPS for the current fiscal year.

Synlogic Company Profile

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.